Early and Late Prognosis in Patients With Guillain-Barre Syndrome
NCT06041451
·
clinicaltrials.gov ↗
PHASE4
Phase
UNKNOWN
Status
450
Enrollment
OTHER
Sponsor class
Conditions
Guillain-Barre Syndrome
Interventions
DRUG:
Intravenous Immunoglobulins, Human
DRUG:
Methylprednisolone 500 MG Injection
Sponsor
First Affiliated Hospital of Wenzhou Medical University